Thymalin.
Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia.
Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia. Thymalin is research / preclinical, and PepCue grades its published evidence D tier (39/100). Also known as thymus peptide extract. This is a research reference, not medical or dosing advice.
What it is
Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia. It belongs to the family of so-called peptide bioregulators and is associated with short peptide sequences (notably Lys-Glu and Glu-Trp) proposed as its active elements. It is positioned as a thymic immunomodulator intended to counter age-related decline of the thymus and T-cell immunity. In Russia it is a registered pharmaceutical; elsewhere it is treated as a research compound.
How it works
Thymalin is proposed to act as an immune bioregulator that supports differentiation and function of T-lymphocytes and helps normalize the T-helper/T-suppressor balance. The Khavinson group hypothesizes that its constituent short peptides can enter cells and interact with DNA and chromatin to modulate tissue-specific gene expression, nudging an aged or dysregulated immune system toward a more youthful pattern. Some experimental work reports effects on the differentiation of hematopoietic stem cells. These proposed mechanisms are largely derived from the originating laboratory's own animal and cell studies rather than from independent mechanistic confirmation.
Mechanism pathways
Short peptides hypothesized to enter cells and influence tissue-specific gene expression.
This group is defined by a shared hypothesis rather than a shared receptor, and the hypothesis is what makes it unusual. The peptide bioregulator concept originated in a single research programme in Russia beginning in the 1970s, initially with peptide extracts prepared from animal organs and later with very short synthetic peptides, typically two to four amino acids, said to reproduce the extracts' activity. The proposal is that these peptides are small enough to cross both the cell membrane and the nuclear envelope without a dedicated transporter, bind directly to DNA promoter regions or to histones, alter chromatin accessibility, and thereby switch on genes that have become silenced with age. Each peptide is claimed to be tissue-specific, acting on the organ its parent extract came from, so a thymus-derived preparation is proposed to act on immune tissue, a pineal-derived one on the pineal gland, and so on. Supporting observations cited by the originating group include reports that some of these peptides bind oligonucleotides in biophysical assays, that fluorescently labelled versions enter the nuclei of cultured cells, and that microarray studies show altered gene expression in treated animal tissues. Reported downstream effects vary by peptide and include changes in immune cell populations, antioxidant enzyme expression, apoptosis markers, and neurotransmitter-related gene expression. The honest assessment must be direct, because this pathway is unusually vulnerable to overstatement. Almost all of the mechanistic and outcome evidence originates from the same laboratory and its close collaborators, published substantially in Russian-language or low-circulation journals, and it has not been independently replicated by unaffiliated groups. Sequence-specific DNA binding by a two-, three-, or four-residue peptide is chemically difficult to reconcile with what is known about how transcription factors achieve specificity, since recognition of a unique genomic site generally requires a much larger binding surface. Longevity and health claims attached to these compounds frequently rest on studies that were not blinded, not randomised, or not controlled, and that were conducted by the same group that developed the products. None of these compounds is an approved medicine in the United States, the European Union, or the United Kingdom, though some have regulatory status in Russia and neighbouring countries. Material sold internationally is unregulated. The proposed mechanism should be understood as an unconfirmed hypothesis, not an established pathway.
The evidence
The published evidence for thymalin comes overwhelmingly from Vladimir Khavinson and collaborators, appearing mainly in Russian-language journals and outlets such as Bulletin of Experimental Biology and Medicine and Neuro Endocrinology Letters. The most cited human data is a multi-year, non-blinded geroprotection program in elderly subjects reporting improved immune parameters and lower mortality versus controls, but it was not a modern blinded, independently replicated randomized controlled trial. That program was reported retrospectively across several summary papers rather than as a single prespecified protocol, and the published accounts do not describe randomization procedure, allocation concealment, blinded outcome assessment, prespecified primary endpoints, or independent data monitoring. Companion reviews such as the 2002 Neuro Endocrinology Letters paper on peptides and ageing present thymalin alongside epithalamin as part of a single geroprotective program, so the human results for the two preparations are frequently reported together rather than separately. More recent papers describe effects on hematopoietic stem cell differentiation and gene expression, again largely from the same group and largely in cell culture, including work on peptide regulation of immune and inflammatory pathways in spleen tissue and in monocyte and macrophage cell lines. Independent Western replication in rigorous RCTs is essentially absent, so the evidence base should be read as preliminary and heavily single-source. Readers should weigh the near-total reliance on one research group when interpreting any claims. The contrast with Cerebrolysin is a useful calibration: Cerebrolysin, another animal-tissue peptide preparation, has accumulated enough independent randomized trials to support two Cochrane systematic reviews, and those reviews still reached cautious and largely non-endorsing conclusions. Thymalin has not reached even that level of external scrutiny, and it shares this position with the other bioregulators in the same tradition, notably vilon, cortexin and epitalon. What is not known is substantial: there is no published modern toxicology package, no pharmacokinetic characterization of the fraction in humans, no batch-to-batch potency standard visible in the international literature, and no registration-quality trial outside Russia.
The evidence, in brief
A thymus-derived peptide preparation from Khavinson's group, proposed as an immune bioregulator against age-related thymic decline. The most-cited human result is a multi-year, non-blinded geroprotection program in elderly subjects, not a modern randomized controlled trial, and the literature is almost entirely single-source from one Russian research group. It is a registered medicine in Russia but has no FDA or EMA approval and no independent Western replication.
- Khavinson VKh et al.: Thymalin: Activation of Differentiation of Human Hematopoietic Stem CellsBull Exp Biol Med, 2020 (PMID 33237528)
- Geroprotective effect of thymalin and epithalamin (in Russian)Adv Gerontol, 2002 (PMID 12577695)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #064
Mostly preclinical or mechanistic; little human data.
Studied in human clinical trials; evidence is meaningful.
Claim receipts
Popular claims about Thymalin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
The supporting work comes overwhelmingly from a single Russian research group and has not been independently replicated.
The most cited human data is a non-blinded multi-year program reported retrospectively by the originating group, without described randomization or blinded outcome assessment.
It is a registered medicine in Russia, but it has no FDA or EMA approval and no independent Western randomized trials.
Animal-sourced injectable preparations carry hypersensitivity and immunogenicity concerns, and the absence of reported harms in single-group publications is not positive safety evidence.
Safety profile
Reported human and animal experience describes thymalin as generally well tolerated in the contexts studied, with few documented serious adverse effects in the originating literature. However, because independent long-term safety data and modern regulatory review outside Russia are lacking, its safety profile in broad populations is not well established, and the absence of reported harms in single-group publications is weak evidence of safety rather than positive evidence of it. As a parenteral preparation derived from calf tissue, it carries the generic concerns that apply to all animal-sourced injectable biologicals: hypersensitivity and anaphylactoid reactions to foreign protein, immunogenicity on repeated exposure, injection-site reactions, and dependence on the source herd and the purification process for freedom from adventitious agents. An agent proposed to modulate T-cell function also raises a theoretical question in autoimmune disease and in people taking immunosuppressive therapy, and that question has not been studied. Product purity and identity are also uncertain for material obtained outside regulated pharmaceutical channels, where lyophilized vials sold as research chemicals carry no verified sterility, endotoxin or content assay. A genuine safety evaluation would require what the existing literature does not provide: prospective adverse-event capture, immunological and hepatic and renal laboratory monitoring, anti-drug antibody testing, and follow-up long enough to detect delayed effects. This is educational information only and not medical or dosing advice.
Compound notes
- Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus, developed by Vladimir Khavinson's group in the Soviet Union and Russia.
- It belongs to the family of peptide bioregulators and is associated with short sequences, notably Lys-Glu and Glu-Trp, proposed as its active elements.
- It is positioned as a thymic immunomodulator meant to counter age-related decline in T-cell immunity, with proposed effects on the T-helper/T-suppressor balance.
- The published evidence comes overwhelmingly from Khavinson and collaborators, largely in Russian-language journals; the most cited human data is a non-blinded multi-year geroprotection program, not a modern blinded randomized trial.
Thymalin is the natural thymic extract fraction; vilon is the synthetic dipeptide Lys-Glu modeled on those active sequences. Both come from the same Russian research tradition.
- Registered as an approved medicine in Russia, but not approved by the FDA or EMA, where it would be treated as an unapproved research substance.
- Independent long-term safety data and modern regulatory review outside Russia are lacking, so its profile in broad populations is not well established.
- Independent Western replication in rigorous randomized trials is essentially absent; weigh the near-total reliance on a single research group.
Regulatory status
Thymalin is registered and used as an approved medicine in Russia, where it has a long clinical history. It is not approved by the US FDA or the European Medicines Agency and has no approved indication in the US, where it would be considered an unapproved research substance. It is not a dietary supplement.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Peptide fraction originally isolated from calf thymus
- 02Developed by Khavinson's group as a peptide bioregulator
- 03Proposed to restore age-related decline in T-cell immunity
- 04Evidence is overwhelmingly from one Russian research group
- 05Registered medicine in Russia; not FDA or EMA approved
- 06Lacks independent Western randomized controlled trials
Thymalin: research formats
Choose the format you are researching to see route-specific notes.
Registered and used as an approved medicine in Russia; outside Russia it is an unapproved research substance.
Thymalin is a peptide fraction originally isolated from calf thymus and developed by the Khavinson group as a thymic immunomodulator. It is registered and used as an approved medicine in Russia, where it has its own approved product information, which this page does not reproduce. In the United States there is no approved product, no label, and no established administration format, so no example schedule or concentration math is presented here.
The evidence base is overwhelmingly from one Russian research group and lacks independent Western randomized controlled trials, so a registration in one market should not be read as a validated format elsewhere.
In the US, thymalin would be considered an unapproved research substance. It is not a dietary supplement.
Sources
Every factual claim above resolves to a real, published source.
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem CellsKhavinson VKh, et al. Bull Exp Biol Med. 2020 (PMID 33237528)
- Geroprotective effect of thymalin and epithalamin (in Russian)Adv Gerontol. 2002 (PMID 12577695)
- PubMed search: thymalin peptide immunityLive PubMed query, mostly single-group Russian literature
- Peptides and AgeingKhavinson VKh. Neuro Endocrinol Lett. 2002 (PMID 12374906)
- Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process (in Russian)Chervyakova NA, Linkova NS, et al. Adv Gerontol. 2014 (PMID 28976144)
- PubMed search: thymalin randomized controlled trialLive PubMed query showing the absence of independent registration-quality trials
Cite this page
PepCue. “Thymalin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/thymalin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.